The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.
The Serious Illness Care Program (SICP) is an evidence-based intervention to enhance serious illness conversations between physicians and patients with advanced cancer. It consists of the Serious Illness Conversation Guide as well as training and system-level support for clinicians to conduct serious illness conversations. The investigators have previously adapted the SICP to be delivered via telehealth for older adults with myeloid malignancies. In this study, they will conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program compared to an education control.
Age ≥60 years A diagnosis of acute myeloid leukemia, myelodysplastic syndrome (MDS), or similar myeloid malignancies (including but not limited to MDS/myeloproliferative neoplasms overlap syndrome, myelofibrosis) Being managed in the outpatient settings Able to provide informed consent English-speaking
Exclusion Criteria:
- None
Inclusion and Exclusion Criteria for Caregivers
Inclusion criteria:
Age ≥18 years Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters" Able to provide informed consent English-speaking
Exclusion criteria
- None
Inclusion and Exclusion Criteria for Oncology Providers
Inclusion criteria:
- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit
